trending Market Intelligence /marketintelligence/en/news-insights/trending/577wrbs9vfarjknyn6ixvg2 content esgSubNav
In This List

Bayer books drop in Q3 profit, confirms full-year outlook

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bayer books drop in Q3 profit, confirms full-year outlook

Bayer AG said third-quarter profit fell year over year and confirmed its outlook for the full year.

The German drug and chemicals company said third-quarter core net income from continuing operations was €1.17 billion, or €1.19 per share, down from €1.29 billion, or €1.45 per share, a year earlier.

The S&P Global Market Intelligence consensus EPS estimate for the quarter is €1.05.

Sales for the quarter reached €9.91 billion, up 23.4% year over year from €8.03 billion. Pharmaceutical sales rose 2.4% year over year on a reported basis to €4.16 billion, with Bayer's best-selling blood-thinning drug Xarelto booking sales of €933 million — a 16.8% growth from the third quarter of 2017.

The company's crop sciences segment saw third quarter sales of €3.73 billion, an 83.8% jump from a year earlier. Bayer's $62.5 billion purchase of Monsanto Co. reshaped the German company's revenue streams, giving greater prominence to a crop sciences unit once in the shadow of its pharmaceutical and consumer health businesses.

Research and development expenses rose to €1.18 billion in the third quarter, up from €1.08 billion in 2017.

For the first nine months of 2018, Bayer recorded core net income from continuing operations of €4.56 billion, or €4.92 per share, down from €4.65 billion, or €5.25 per share, in the same period last year.

Sales for the nine-month period reached €28.52 billion, up 8% year over year from €26.42 billion in the previous year.

For full year 2018, the company still expects core EPS to decline by a high-single-digit percentage and be between €5.70 and €5.90.

The S&P Global Market Intelligence consensus normalized EPS estimate for 2018 is €5.78.

Further, Bayer still expects sales of more than €39 billion in 2018, or a mid-single-digit percentage increase for the full year.